ANVS - Annovis Bio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.4400
-0.1100 (-3.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.5500
Open3.2102
Bid2.2300 x 900
Ask3.8100 x 1000
Day's Range3.2102 - 3.4400
52 Week Range0.0200 - 10.6100
Volume7,244
Avg. Volume194,173
Market Cap23.548M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Annovis Bio to Present at the Online Spring Investor Summit on March 25

    NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases, is ...

  • GlobeNewswire

    Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies

    Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other neurodegenerative diseases, was awarded a $1.7 million grant from the National Institutes of Health (NIH) for the Company’s long-term toxicology studies in rats and in dogs of its lead therapeutic compound ANVS401. Annovis previously conducted one-month safety studies in mice, rats and dogs, and conducted two human safety studies in 120 healthy volunteers. In an interim analysis of an ongoing Phase 2a clinical trial in AD patients, the Data Safety Monitoring Board recommended the trial continue without modification.

  • GlobeNewswire

    Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases

    Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia and other Lewy body diseases in humans by administering its lead compound, ANVS401. The Company expects multiple patents to be generated from this patent family, each targeting specific neurodegenerative diseases independently.

  • GlobeNewswire

    Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease

    Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced today that the Data Safety Monitoring Board has reviewed the safety data, enrollment, participant status, demographic data and vital signs of patients enrolled in their Phase II clinical trial for the treatment of Alzheimer’s disease and unanimously supported that the study, which is named DISCOVER, continue without modification. The clinical trial taking place at six sites, including the University of California, San Diego, Johns Hopkins, Indiana University, Washington University, the Cleveland Clinic and Columbia University, is a 24-patient study.

  • GlobeNewswire

    Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases, today announced the closing of its initial public offering of 2,000,000 shares of its common stock at the public offering price of $6.00 per share, and the full exercise by the underwriters of their option to purchase 300,000 additional shares of Annovis Bio’s common stock. The exercise of the option brings the total number of shares of common stock sold by Annovis Bio to 2,300,000 shares. The gross proceeds from Annovis Bio’s initial public offering, including proceeds from the exercise of the underwriters’ option to purchase additional shares, were approximately $13.8 million, before deducting underwriting discounts, commissions and offering expenses payable by Annovis Bio.

  • GlobeNewswire

    Annovis Bio Announces Pricing of Initial Public Offering

    Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a price to the public of $6.00 per share, for gross proceeds of $12,000,000 before deducting underwriting discounts, commissions and offering expenses. In addition, Annovis Bio, Inc. has granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of its common stock to cover over-allotments at the initial public offering price less underwriting discount. All of the shares of common stock are being offered by Annovis Bio, Inc.